English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Between 2.5 and 5 persons per 100,000 become ill with neuroendocrine carcinoma of the breast per year, and in autopsy studies, occurrence is found 2 5 times more often. Approximately 70% of neuroendocrine tumours are tumours of the gastrointestinal tract and pancreatic tumours [3] . In recent years, there is an observed increase in the incidence of neuroendocrine tumours which inevitably has to do with the improvement of detection but also indicates a greater effectiveness of diagnostic methods.

Neuroendocrine Carcinoma of the Breast – Preliminary Analysis of Treatment Results of 30 Patients